Fiche publication
Date publication
novembre 2014
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FAVIER Laure
Tous les auteurs :
Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E
Lien Pubmed
Résumé
Lenalidomide has dual antiangiogenic and immunomodulatory properties and confirmed antitumor activity in hematologic malignancies. A phase II study investigating the safety and efficacy of continuous lenalidomide in recurrent ovarian cancer patients was initiated.
Mots clés
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, CA-125 Antigen, blood, Carcinoma, Ovarian Epithelial, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions, pathology, Fallopian Tube Neoplasms, Female, Humans, Lenalidomide, Membrane Proteins, blood, Middle Aged, Neoplasm Recurrence, Local, chemically induced, Neoplasm Staging, Neoplasms, Glandular and Epithelial, blood, Ovarian Neoplasms, blood, Platinum, adverse effects, Thalidomide, administration & dosage
Référence
Ann. Oncol.. 2014 Nov;25(11):2191-6
